David Sommerhalder, MD, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer.
David Sommerhalder, MD
Advertisement
Articles by David Sommerhalder, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5